Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders: Role of the Glutamatergic System

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 273-291

  Zarate Jr , Carlos A ^a   Du, Jing ^a   Quiroz, Jorge ^a   Gray, Neil A ^a   Denicoff, Kirk D ^a   Singh, Jaskaran ^a   Charney, Dennis S ^a   Manji, Husseinik ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Bipolar disorder; Depression; Glutamate; Memantine; Mood stabilizer; NMDA AMPA kainate; Riluzole

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; AMANTADINE; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLOSERINE; DESIPRAMINE; DIZOCILPINE; FLUOXETINE; GLUCOCORTICOID; GLUTAMIC ACID; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LITHIUM; LY 392098; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENELZINE; RILUZOLE; SULFONAMIDE; UNCLASSIFIED DRUG; VALPROIC ACID;

BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN NERVE CELL; BRAIN REGION; BRAIN SIZE; CELL COUNT; CELL DENSITY; CELL SIZE; CELL STRUCTURE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; GENETIC ANALYSIS; GLIA CELL; HUMAN; IMAGE ANALYSIS; MENTAL PATIENT; MOOD DISORDER; MORPHOMETRICS; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRESS; STRUCTURE ANALYSIS;

EID: 0347722453     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.017     Document Type: Conference Paper

References (127)

1. MANJI, H.K., W.C. DREVETS & D.S. CHARNEY. 2001. The cellular neurobiology of depression. Nat. Med. 7: 541-547.
2. NESTLER, E.J., M. BARROT, R.J. DILEONE, et al. 2002. Neurobiology of depression. Neuron 34: 13-25.
3. DREVETS, W.C. 2001. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11: 240-249.
4. MANJI, H.K. & R.H. LENOX. 2000. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol. Psychiatry 48: 518-530.
5. PAYNE, J.L., J.A. QUIROZ, C.A. ZARATE & H.K. MANJI. 2002. Timing is everything: Does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol. Psychiatry. In press.
6. MANJI, H.K., G.J. MOORE, G. RAJKOWSKA & G. CHEN. 2000. Neuroplasticity and cellular resilience in mood disorders. Millennium Article. Mol. Psychiatry. 5: 578-593.
7. D'SA, C. & R. DUMAN. 2002. Antidepressants and neuroplasticity. Bipolar Disorder 4: 183.
8. YOUNG, L.T. 2002. Neuroprotective effects of antidepressant and mood stabilizing drugs. J. Psychiatry Neurosci. 27: 8-9.
9. MANJI, H. & R. DUMAN. 2001. Impairments of neuroplasticity and cellular resilience in severe mood disorder: implications for the development of novel therapeutics. Psychopharmacol. Bull. 35: 5-49.
10. STRAKOWSKI, S.M., C.M. ADLER & M.P. DELBELLO. 2002. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord. 4: 80-88.
11. BEYER, J.L. & K.R. KRISHNAN. 2002. Volumetric brain imaging findings in mood disorders. Bipolar Disord. 4: 89-104.
12. LENOX, R.H., T.D. GOULD & H.K. MANJI. 2002. Endophenotypes in bipolar disorder. Am. J. Med. Genet. 114: 391-406.
13. CARMELLI, D., T. REED & C. DECARLI. 2002. A bivariate genetic analysis of cerebral white matter hyperintensities and cognitive performance in elderly male twins. Neurobiol. Aging 23: 413-420.
14. TAYLOR, W.D., M.E. PAYNE, K.R. KRISHNAN, et al. 2001. Evidence of white matter tract disruption in MRI hyperintensities. Biol. Psychiatry 50: 179-183.
15. STOLL, A.L., P.F. RENSHAW, D.A. YURGELUN-TODD & B.M. COHEN. 2000. Neuroimaging in bipolar disorder: what have we learned? Biol. Psychiatry 48: 505-517.
16. COTTER, D., D. MACKAY, S. LANDAU, et al. 2001. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 58: 545-553.
17. RAJKOWSKA, G. 2002. Cell pathology in bipolar disorder. Bipolar Disord. 4: 105-116.
18. COYLE, J.T. & R. SCHWARCZ. 2000. Mind glue: implications of glial cell biology for psychiatry. Arch. Gen. Psychiatry 57: 90-93.
19. HAYDON, P.G. 2001. GLIA: listening and talking to the synapse. Nat. Rev. Neurosci. 2: 185-193.
20. ONGUR, D., W.C. DREVETS & J.L. PRICE. 1998. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 95: 13290-13295.
21. RAJKOWSKA, G., J.J. MIGUEL-HIDALGO, J. WEI, et al. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45: 1085-1098.
22. RAJKOWSKA, G. 2000. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry. 48: 766-777.
23. ULLIAN, E.M., S.K. SAPPERSTEIN, K.S. CHRISTOPHERSON & B.A. BARRES. 2001. Control of synapse number by glia. Science 291: 657-661.
24. LOPEZ, J.F., D.T. CHALMERS, K.Y. LITTLE, et al. 1998. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry. 43: 547-573.
25. SAPOLSKY, R.M. 2000. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57: 925-935.
26. MCEWEN, B.S. 1999. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 22: 105-122.
27. SAPOLSKY, R.M. 1996. Stress, glucocorticoids, and damage to the nervous system: The current state of confusion. Stress 1: 1-19.
28. SANCHEZ, M.M., L.J. YOUNG, P.M. PLOTSKY & T.R. INSEL. 2000. Distribution of corticosteroid receptors in the rhesus brain: relative absence of glucocorticoid receptors in the hippocampal formation. J. Neurosci. 20: 4657-4668.
29. PATEL, P.D., J.F. LOPEZ, D.M. LYONS et al. 2000. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J. Psychiatr. Res. 34: 383-392.
30. SAPOLSKY, R.M. 2000. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry 48: 755-765.
31. MAURI, M.C., A. FERRARA, L. BOSCATI, et al. 1998. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37: 124-129.
32. MATHIS, P., L. SCHMITT, M. BENATIA, et al. 1988. [Plasma amino acid disturbances and depression]. Encephale 14: 77-82.
33. ALTAMURA, C.A., M.C. MAURI, A. FERRARA, et al. 1993. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150: 1731-1733.
34. ALTAMURA, C., M. MAES, J. DAI & H.Y. MELTZER. 1995. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 5 (Suppl.): 71-75.
35. MAES, M., R. VERKERK, E. VANDOOLAEGHE, et al. 1998. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 97: 302-308.
36. LEVINE, J., K. PANCHALINGAM, A. RAPOPORT, et al. 2000. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 47: 586-593.
37. BERK, M., H. PLEIN & D. FERREIRA. 2001. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin. Neuropharmacol. 24: 129-132.
38. NOWAK, G., G.A. ORDWAY & I.A. PAUL. 1995. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 675: 157-164.
39. COUSINS, J.P. & G. HARPER. 1996. Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression. Cancer Lett. 110: 163-167.
40. AUER, D.P., B. PUTZ, E. KRAFT, et al. 2000. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 47: 305-313.
41. PFLEIDERER, B.,N. MICHAEL, A. ERFURTH, et al. 2003. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 122: 185-192.
42. CASTILLO, M., L. KWOCK, H. COURVOISIE & S.R. HOOPER. 2000. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. Am. J. Neuroradiol. 21: 832-838.
43. MICHAEL, M. A. ERFURTH, P. OHRMANN, et al. 2003. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003.
44. BOURON, A. & J.Y. CHATTON. 1999. Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90: 729-736.
45. MICHAEL-TITUS, A.T., S. BAINS, J. JEETLE & R. WHELPTON. 2000. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100: 681-684.
46. 2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. Eur. J. Pharmacol. 247: 101-102.
47. PAUL, I.A., R. TRULLAS, P. SKOLNICK & G. NOWAK. 1992. Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology (Berl). 106: 285-287.
48. NOWAK, G., Y. LI & I.A. PAUL. 1995. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur. J. Pharmacol. 295: 75-85.
49. BOYER, P.A., P. SKOLNICK & L.H. FOSSOM. 1998. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 10: 219-233.
50. SKOLNICK, P. 1999. Antidepressants for the new millennium. Eur. J. Pharmacol. 375: 31-40.
51. POPE, H.G., JR., S.L. MCELROY, P.E. KECK, JR. & J.I. HUDSON. 1991. Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry 48: 62-68.
52. BOWDEN, C.L., A.M. BRUGGER, A.C. SWANN, et al. 1994. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J. Am. Med. Assoc. 271: 918-924.
53. NONAKA, S. & D.M. CHUANG. 1998. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9: 2081-2084.
54. HASHIMOTO, R., C. HOUGH, T. NAKAZAWA, et al. 2002. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 80: 589-597.
55. KARKANIAS, N.B. & R.L. PAPKE. 1999. Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci. Lett. 277: 153-156.
56. LOSCHER, W. 1993. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. 18: 485-502.
57. COLLINS, R.M., JR., H.R. ZIELKE & R.C. WOODY. 1994. Valproate increases glutaminase and decreases glutamine synthetase activities in primary cultures of rat brain astrocytes. J. Neurochem. 62: 1137-1143.
58. DIXON, J.F. & L.E. HOKIN. 1997. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4, 5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc. Natl. Acad. Sci. USA 94: 4757-4760.
59. 2+ transients in primary astroglial cultures - modulatory effects of valproic acid. Glia 5: 201-209.
60. UEDA, Y. & L.J. WILLMORE. 2000. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp. Brain Res. 133: 334-339.
61. HASSEL, B., E.G. IVERSEN, L. GJERSTAD & E. TAUBOLL. 2001. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J. Neurochem. 77: 1285-1292.
62. LOSCHER, W. 1999. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58: 31-59.
63. 3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus. Epilepsy Res. 31: 153-157.
64. BOLANOS, A.R., M. SARKISIAN, Y. YANG, et al. 1998. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 51: 41-48.
65. TURSKI, L. 1990. [The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences]. Arzneimittelforschung 40: 511-514.
66. STEPPUHN, K.G. & L. TURSKI. 1993. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 265: 1063-1070.
67. JING, D., N.A. GRAY, C.S. FALKE, et al. 2002. The mood stabilizer lithium regulates the synaptic and total protein expression of AMPA glutamate receptors in vitro and in vivo. Soc. Neurosci. Vol. Program No. 308. Washington, D.C.
68. SAAL, D., Y DONG, A. BONCI & R.C. MALENKA. 2003. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 37: 577-582.
69. Li, X., J.P. TIZZANO, K. GRIFFEY, et al. 2001. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40: 1028-1033.
70. LAUTERBORN, J.C., G. LYNCH, P. VANDERKLISH, et al. 2000. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20: 8-21.
71. YUAN, P.X., L.D. HUANG, Y.M. JIANG, et al. 2001. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 276: 31674-31683.
72. ADAMS, J.M. & S. CORY, 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
73. BONNI, A., A. BRUNET, A.E. WEST, et al. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362.
74. CHEN, D.F., G.E. SCHNEIDER, J.C. MARTINOU & S. TONEGAWA. 1997. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 385: 434-439.
75. FINKBEINER, S. 2000. CREB couples neurotrophin signals to survival messages. Neuron 25: 11-14.
76. PETTMANN, B. & C.E. HENDERSON. 1998. Neuronal cell death. Neuron 20: 633-647.
77. RICCIO, A., S. AHN, C.M. DAVENPORT, et al. 1999. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286: 2358-2361.
78. THOENEN, H. 1995. Neurotrophins and neuronal plasticity. Science 270: 593-598.
79. CHEN, G., H. EINAT, P. YUAN & H. MANJI. 2002. Evidence for the involvement of the MAP/ERK signaling pathway in mood modulation. Biol. Psychiatry 51: 126S.
80. CHEN, G., W.Z. ZENG, P.X. YUAN, et al. 1999. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72: 879-882.
81. MANJI, H., J. Du & T. GOULD. 2002. The role of neurotrophic signaling pathways in mood disorders. In Signal Transduction and Human Disease. J. Gutkind, Ed. In press.
82. CHEN, G., L.D. HUANG, W.Z. ZENG & H.K. MANJI. 2001. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. Int. J. Neuropsychopharmacol. 4: 47-64.
83. WEI, H., Z.H. QIN, V.V. SENATOROV, et al. 2001. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106: 603-612.
84. TSAI, G. & J.T. COYLE. 1995. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46: 531-540.
85. MOORE, G.J., J.M. BEBCHUK, K. HASANAT, et al. 2000. Lithium increases N-acetylaspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol .Psychiatry 48: 1-8.
86. MOORE, G.J., J.M. BEBCHUK, I.B. WILDS, et al. 2000. Lithium-induced increase in human brain grey matter. Lancet 356: 1241-1242.
87. MOORE, G., R. RAJARETHINAM, B. CORTESE, et al. 2001. Regionally specific increases in human brain gray matter with chronic lithium treatment. Soc. Neurosci. (Abstr.) 27: (Program No. 111.118).
88. AREOSA, S.A. & F. SHERRIFF. 2003. Memantine for dementia. Cochrane Database Syst Rev. VCD003154.
89. ORGOGOZO, J.M., A.S. RIGAUD, A. STOFFLER, et al. 2002. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834-1839.
90. REISBERG, B., R. DOODY, A. STOFFER, et al. 2003. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348: 1333-1341.
91. BORMANN, J. 1989. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166: 591-592.
92. 3H]MK-801 binding to human hippocampal NMDA receptors. Neuroreport 5: 1237-1240.
93. KORNHUBER, J., K. SCHOPPMEYER & P. RIEDERER. 1993. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci. Lett. 163: 129-131.
94. CHEN, H.S., Y.F. WANG, P.V. RAYUDU, et al. 1998. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86: 1121-1132.
95. CHEN, H.S. & S.A. LIPTON. 1997. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499: 27-46.
96. MORYL, E., W. DANYSZ & G. QUACK. 1993. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72: 394-397.
97. ROGOZ, Z., G. SKUZA, J. MAJ & W. DANYSZ. 2002. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42: 1024-1030.
98. AMETAMEY, S.M., S. SAMNICK, K.L. LEENDERS, et al. 1999. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. J. Recept. Signal Transduct. Res. 19: 129-141.
99. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166: 589-590.
100. KORNHUBER, J., M. WELLER, K. SCHOPPMEYER & P. RIEDERER. 1994. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. Suppl. 43: 91-104.
101. BENAVIDES, J., J.C. CAMELIN, N. MITRANI, et al. 1985. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission - II. Biochemical properties. Neuropharmacology 24: 1085-1092.
102. KRETSCHMER, B.D., U. KRATZER & W.J. SCHMIDT. 1998. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch. Pharmacol. 358: 181-190.
103. DOBLE, A. 1996. The pharmacology and mechanism of action of riluzole. Neurology 47: 8233-241.
104. URBANI, A. & O. BELLUZZI. 2000. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur. J. Neurosci. 12: 3567-3574.
105. BENOIT, E. & D. ESCANDE D. 1991. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflug. Arch. 419: 603-609.
106. CHERAMY, A., L. BARBEITO, G. GODEHEU & J. GLOWINSKI. 1992. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 147: 209-212.
107. MARTIN, D., M.A. THOMPSON & J.V. NADLER. 1993. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CAl. Eur. J. Pharmacol. 250: 473-476.
108. DEBONO, M.W., J. LE GUERN, T. CANTON, et al. 1993. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 235: 283-289.
109. SINISCALCHI, A., A. BONCI, N.B. MERCURI & G. BERNARDI. 1997. Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study. Br. J. Pharmacol. 120: 225-230.
110. DE SARRO, G., A. SINISCALCHI, G. FERRERI, et al. 2000. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur. J. Pharmacol. 408: 25-34.
111. HUBERT, J.P., M.C. BURGEVIN, F. TERRO, et al. 1998. Effects of depolarizing stimuli on calcium homeostasis in cultured rat motoneurones. Br. J. Pharmacol. 125: 1421-1428.
112. Keita, H., C. Lepouse, D. Henzel, et al. 1997. Riluzole blocks dopamine release evoked by N-methyl-D-aspartate, kainate, and veratridine in the rat striatum. Anesthesiology 87: 1164-1171.
113. MIZUTA, I., M. OHTA, K. OHTA, et al. 2001. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 310: 117-120.
114. SHIRAYAMA, Y., A.C. CHEN, S. NAKAGAWA, et al. 2002. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22: 3251-3261.
115. ZARATE, C.A., JR., J. QUIROZ, J. PAYNE & H.K. MANJI. 2002. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol. Bull. 36: 35-83.
116. BERMAN, R.M., A. CAPPIELLO, A. ANAND, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47: 351-354.
117. CALABRESE, J.R., C.L. BOWDEN, G.S. SACHS, et al. 1999. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60: 79-88.
118. CRANE, G. 1959. Cycloserine as an antidepressant agent. Am. J. Psychiatry 115: 1025-1026.
119. 3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res. 616: 138-143.
120. MEADOR-WOODRUFF, J.H., A.J. HOGG JR. & R.E. SMITH. 2001. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 55: 631-640.
121. PAPP, M. & E. MORYL. 1996. Antidepressant-like effects of 1-aminocyclopropane-carboxylic acid and D-cycloserine in an animal model of depression. Eur. J. Pharmacol. 316: 145-151.
122. PARKES, J.D., D.M. CALVER, K.J. ZILKHA & R.P. KNILL-JONES. 1970. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1: 259-262.
123. REYNOLDS, I.J. & R.J. MILLER. 1988. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br. J. Pharmacol. 95: 95-102.
124. STRYJER, R., R.D. STROUS, G. SHAKED, et al 2003. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. 18: 93-96.
125. TRULLAS, R. & P. SKOLNICK. 1990. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185: 1-10.
126. VALE, S., M.A. ESPEJEL & J.C. DOMINGUEZ. 1971. Amantadine in depression. Lancet 2: 437.
127. ZARATE, C.A J., J.L. PAYNE, J. QUIROZ, et al. An open-label trial of riluzole in treatment-resistant major depression. Am. J. Psychiatry. In press.